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Hendra and Nipah viruses (HeV and NiV) are closely related zoonotic pathogens of the Paramyxoviridae
family. Both viruses belong to the Henipavirus genus and cause fatal disease in animals and humans,
though only HeV is endemic in Australia. In general and due to the acute nature of the disease, agent
detection by PCR and virus isolation are the primary tools for diagnostic investigations. Assays for the
detection of antibodies against HeV are ﬁt more readily for the purpose of surveillance testing in disease epidemiology and to meet certiﬁcation requirements in the international movement of horses. The
ﬁrst generation indirect ELISA has been affected by non-speciﬁc reactions which must be resolved using
virus neutralisation serology conducted at laboratory bio-safety level 4 containment (PC4). Recent developments have enabled improvements in the available serology assays. The production of an expressed
recombinant truncated HeV G protein has been utilised in ELISA and in Luminex-based multiplexed
microsphere assays. In the latter format, two Luminex assays have been developed for use in henipavirus
serology: a binding assay (designed for antibody detection and differentiation) and a blocking assay
(designed as a surrogate for virus neutralisation). Equine and canine ﬁeld sera were used to evaluate the
two Luminex assays relative to ELISA and virus neutralisation serology. Results showed that Luminex
assays can be effective as rapid, sensitive and speciﬁc tests for the detection of HeV antibody in horse and
dog sera. The tests do not require PC4 containment and are appropriate for high throughput applications
as might be required for disease investigations and other epidemiological surveillance. Also, the results
show that the Luminex assays detect effectively HeV vaccine-induced antibodies.
© 2014 Elsevier B.V. All rights reserved.

1. Introduction
Hendra virus (HeV) and Nipah virus (NiV) belong to the Henipavirus genus within the Paramyxoviridae family (Eaton et al., 2007).
HeV was detected ﬁrst following an outbreak of a severe and fatal
respiratory disease in a large racing stable in the suburb of Hendra,
Brisbane in 1994. Since the initial HeV outbreak, sporadic spill-over
events have occurred annually in Australia across Queensland and
northern New South Wales. The natural reservoir of these zoonotic
agents is within the genus Pteropus (Haplin et al., 2011), commonly
known as fruit bats or ﬂying foxes. This disease is usually fatal in
horses with over 80 horses having died or been euthanised due to
infection with HeV; furthermore four of the seven humans known

Abbreviations: HeV, Hendra virus; NiV, Nipah virus; %P, percent positive; %I,
percent inhibition; MFI, median ﬂuorescence intensity.
∗ Corresponding author. Tel.: +61 352275128; fax: +61 352275555.
E-mail address: Leanne.mcnabb@csiro.au (L. McNabb).
0166-0934/$ – see front matter © 2014 Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.jviromet.2014.01.010

to be infected with HeV have died (Marsh and Wang, 2012). In 2011,
a healthy dog on a HeV affected Qld property was also found to have
high levels of neutralising antibody against HeV (Croser and Marsh,
2013). More recently in November 2012, a commercial equine vaccine against HeV (Equivac HeV, Zoetis Australia P/L) was released
for use in Australia (Mendez et al., 2013; Broder et al., 2013). However, a henipavirus vaccine for humans will take many more years
to develop (Middleton, 2012).
Initially NiV emerged in pigs in Malaysia in 1998 (Chua et al.,
2000); by April 1999, 106 human deaths had occurred in Malaysia
and Singapore (Marsh and Wang, 2012). No further outbreaks of
NiV have been reported in Malaysia, however, in separate outbreaks
the virus continues to spill over and cause disease in other countries
such as Bangladesh and India.
The henipavirus genome is a non-segmented, negative-strand
RNA. The genes encode six major structural proteins; the nucleocapsid (N), phosphoprotein (P), matrix protein (M), fusion protein
(F), attachment glycoprotein (G) and the large polymerase
(L) (Wang et al., 2001). The two major membrane-anchored
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glycoproteins are required for infection of a permissive host cell.
The F glycoprotein mediates pH-independent membrane fusion
between the virus and its host cell (Bossart et al., 2005). The G
glycoprotein is the attachment protein which binds the host cell
via the Ephrin B2 or Ephrin B3 receptors (Bossart et al., 2008).
The G protein of NiV and HeV share 83% nucleotide homology
(Wang et al., 2001) and cross-reactive antibodies against the G protein have been observed between the two viruses (Bossart et al.,
2005).
Laboratory diagnosis of equine infection following a HeV spillover event is critical to management of potentially exposed persons
and animals located on infected premises. Currently, all diagnostic
submissions for HeV exclusion received at CSIRO’s Australian Animal Health Laboratory (AAHL) are tested by PCR and virus isolation.
Due to the fulminant and lethal course of the disease, serology is less
frequently deﬁnitive in the diagnosis of acute infection. However
the technique is appropriate for “proof of freedom” of animals on
affected properties, surveillance and regulation testing of horses
prior to international transport. At the Australian Animal Health
Laboratory (AAHL), HeV serology presently is conducted by indirect
ELISA using either inactivated virus (Daniels et al., 2001; OIE, 2009)
or the more recently introduced recombinant-expressed protein
(Wang and Daniels, 2012; Colling et al., 2013). The latter employs
a form of the G protein (sG), truncated for enhanced solubility
(Bossart et al., 2005). Currently, all serum reactors (positive and
indeterminate) in the iELISAs are resolved by a virus neutralisation
assay which must be performed under strict bio-containment procedures in a PC4 laboratory. The interpretation and validation of
the HeV iELISAs are complicated by the lack of a large number of
test results for positive sera and by the frequency of non-speciﬁc
reactions, particularly in the whole virus ELISA. These also must be
resolved for speciﬁcity by virus neutralisation serology. The development of a rapid and safe microsphere immuno-assay (Luminex
assay) which can be performed in a PC2/PC3 laboratory, will aid in
diagnostic surveillance of this disease.
Two Luminex-based ﬂuorescent microsphere assays have been
developed using an approach described previously by Bossart et al.
(2007) for detection of antibody against henipaviruses. The target
antigen for both assays is recombinant-expressed sG, but the assays
are designed separately in total antibody-binding and restricted
receptor-blocking formats. The Luminex binding assay was used
for antibody detection and differentiation of HeV and NiV whereas
the Luminex blocking assay was designed as a surrogate for virus
neutralisation. The detection of HeV-speciﬁc antibodies in sera
from convalescent horses following HeV infection in Australia using
the henipavirus Luminex binding and blocking assays was ﬁrst
described by Bossart et al. (2007). In addition, these Luminex assays
have been used for further serological studies to detect henipavirus
antibodies in bats and other species internationally including; West
African fruit bats and domestic pigs (Hayman et al., 2008; Hayman
et al., 2011; Peel et al., 2012, 2013), Pteropid bats in Papua New
Guinea (Breed et al., 2010) and Pteropus vampyrus bats in Indonesia
(Sendow et al., 2013). Recently, the Luminex microsphere assay was
used to assess HeV infection in the mouse model (Dups et al., 2012)
and to conﬁrm HeV infection in human cases by Queensland Health
(Playford et al., 2010).
In 2011, a year with an unusually high occurrence of HeV
infections (18 outbreaks) in Australia (Mahalingam et al., 2012),
three dogs from a HeV infected property undergoing quarantine in
Mount Alford, Queensland were assessed by HeV ELISAs and HeV
virus neutralisation serology at AAHL (Croser and Marsh, 2013).
This was the ﬁrst report of a dog infected naturally with HeV in
Australia.
In this study, the Luminex assays were characterised further for
use in detection of HeV speciﬁc antibodies in sera from infected and
non-infected animals including horses and dogs; results have been
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evaluated against assessments using ELISA and virus neutralisation
serology assays.
2. Materials and methods
2.1. Animal sera
All ﬁeld horse and dog sera tested were derived as diagnostic samples submitted to the AAHL; sera were neat or diluted 1:5
in PBS containing 0.5% Tween 20 and 0.5% Triton-X100, and heat
treated at 56 ◦ C for 30 min prior to use. A range of horse, pig, goat,
rabbit and guinea pig anti-sera for use in analytical speciﬁcity (HeVuninfected) assessments were variously derived from naturally or
infected experimentally animals. Sera from HeV vaccinated horses
(AAHL job 12-03417) were received for HeV serology assessment,
though without details of vaccination time or doses.
2.2. Henipavirus Luminex binding and blocking assays
The multiplex microsphere assays have been described previously by Bossart et al. (2007). Brieﬂy, for both assays, HeV or NiV
soluble G (sG) proteins (Bossart et al., 2005) were coupled to individual microsphere sets. In both assays a predetermined number
of polystyrene or magnetic beads (Fisher Biotec Pty Ltd, Australia)
were added to each well and then mixed with test sera at a dilution
of 1:100 (binding assay) or 1:50 (blocking assay). In the binding
assay, bound antibody was detected using biotinylated Protein A
(Pierce, Rockford, USA) together with biotinylated Protein G (Pierce,
Rockford, USA) followed by streptavidin–phycoerythrin (Qiagen
Pty Ltd, Australia). Results were recorded as median ﬂorescent
intensity (M.F.I.), or transformed as a percentage relative to the
MFI for the positive control (%P): [(MFI test serum)/(MFI positive
control serum)] × 100.
For the receptor blocking assay, the presence of HeV antibodies in the serum was detected by the ability to block biotinylated
Ephrin B2 (Sapphire Bioscience Pty Ltd, Australia) which otherwise binds directly to soluble G protein-coated beads (Bossart
et al., 2008). Streptavidin–phycoerythrin was added for detection
of bound Ephrin B2. Low MFI values indicated henipavirus antibodies blocked successfully the binding of the receptor to sG. The
results were recorded as a percentage inhibition and raw MFI readings were converted to percentage inhibition using the following
formula: (1 − [(MFI test serum)/(MFI negative serum)] × 100.
Both assays were read using a Bio-Plex Protein Array System
integrated with Bio-Plex Manager Software (v 4.1) (Bio Rad Laboratories, Inc., CA, USA) for data acquisition and analysis.
2.3. HeV ELISAs
2.3.1. HeV antibody indirect ELISA (HeV iELISA)
This ELISA, using detergent disrupted/inactivated virus antigen
derived from whole cell lysates of HeV-infected Vero cells has been
previously described by Daniels et al. (2001). In brief, NUNC Maxisorb plates were coated with HeV infected and non-infected (mock
antigen) cell lysates diluted in carbonate buffer (pH 9.6) for 1 h at
37 ◦ C. Coating and subsequent binding steps were followed by a
four cycle rinse with wash buffer (PBS + 0.05% Tween 20). Sera were
assessed at a 1:100 dilution in wash buffer with added 1% skim milk
powder for an incubation period of 1 h at 37 ◦ C. Bound antibody was
reacted with a Protein A/G-HRP conjugate (Pierce, Rockford, USA),
30 min at 37 ◦ C. TMB substrate (Sigma-Aldrich Pty Ltd, Australia)
was reacted for 7–10 min before addition of 1 M H2 SO4 . Plates were
read for absorbance at optical density 450 nm. After background
subtraction, a threshold optical density 0.2 was assigned to differentiate positive reactor from negative sera. All reactive sera were
retested in virus neutralisation serology. Signiﬁcant reactions on
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Fig. 1. Limit dilution titration of Luminex binding () and blocking assays () for HeV
sG using a positive serum (Tho) with a virus neutralisation titre 1024.

the mock antigen in association with above threshold OD detections were qualiﬁed for interpretation as “non-speciﬁc reactors”.
2.3.2. HeV antibody indirect ELISA (HeV sG-iELISA)
The ELISA used HeV sG antigen coated at a concentration of
0.23 g/ml. After a coating incubation (1 h at 37 ◦ C), the plate was
blocked with skim milk for 30 min and washed with PBST. Test
sera were diluted 1:100, added to the plate and shaken for 1 h
at 37 ◦ C. Bound antibody was detected by using anti equine-HRP
(Sigma-Aldrich Pty Ltd, Australia) or Protein A/G-HRP conjugate
(Pierce, Rockford, USA) and a TMB substrate. Plates were read for
absorbance at optical density 450 nm. After subtraction of background (taken as the OD from the negative control serum), ODs
were transformed to a ratio relative to a low positive control serum
(average OD approximately 0.5) and a signal to positive S/P ratio
was calculated. A threshold S/P of 0.4 was assigned to differentiate
positive reactor from negative sera. This assay is speciﬁc for equine
sera due to the anti-equine conjugate used in the test. As for the
HeV iELISA, all positive reactor sera in the sG-iELISA were retested
in virus neutralisation serology.
2.4. HeV virus neutralisation serology
A standard virus neutralisation in microplate format was used
for assessing sera for neutralising antibody against HeV (Bossart
et al., 2007; OIE, 2009). The test used Vero cells and a virus concentration of 100 TCID50 /well. Sera were assessed from an initial
dilution of 1:2 and were incubated with virus in a 96 well plate
for 30 min at 37 ◦ C. Vero cells were added and the plates incubated
for 4 days at 37 ◦ C in a CO2 incubator. Cell monolayers were scored
for the presence of cytopathic effect (CPE) and serum neutralisation titres were determined as the reciprocal of the serum dilution
where no CPE was evident.
3. Results
3.1. Analytical sensitivity for the Luminex assays
To determine the analytical sensitivity for the henipavirus
Luminex binding assay, a titration of a seropositive ﬁeld infection
serum (Tho), with a virus neutralisation titre of 1:1024 was performed (Fig. 1). The lower asymptote end point for the curve was
approached at an MFI value of approximately 865 reaching this
point at a dilution of 1:3200. Analytical sensitivity was derived
from a third order polynomial regression curve ﬁtted to the four

Fig. 2. Detection of henipavirus antibodies in a panel of sera from a range of Paramyoxviruses, Flaviviruses and Alphaviruses using the Luminex binding and blocking
assays.

lowest data points (r2 = 1) and applying assay threshold MFI value of
1500. Using HeV Luminex binding assay, the end-point dilution for
positive signal detection was 1:2125. This represents an analytical
detection range of approximately 2 times the assigned virus neutralisation titre (1024). The positive serum (Tho) was designated as
a positive control for use in subsequent assays. In the binding assay
and for the purpose of a normalising data, MFI values for test sera
were transformed relative to the MFI value for the positive serum
to yield a percentage positive (%P) value. The threshold was set at
5%P, being approximately 1500 MFI.
The serum was tested similarly in the Luminex blocking assay,
reaching the lower asymptote at a dilution of 1:800. Using a positive/negative threshold of 15 percent inhibition (%I), detection
to threshold spanned a 1:475 dilution range which is less than
the virus neutralisation range by approximately half. Relative to
the binding assay, the detection range for the blocking assay was
reduced by a factor of 4.48. Taking into account the initial dilution
(1:100 for binding assay and 1:50 for blocking assay), the binding
assay had an analytical sensitivity approximately 9 times that of
the blocking assay.
3.2. Analytical speciﬁcity of Luminex assays
In order to assess the analytical speciﬁcity of the henipavirus
Luminex binding and blocking assays anti-sera against a range of
Paramyxoviridae, Flaviviruses and Alphaviruses were tested.
In the binding format of the assay, one serum not raised against
Henipavirus was marginally above the 5% provisional threshold
with a reaction level of 7%P (Fig. 2). This reactive serum was an
experimentally produced equine antiserum against eastern equine
encephalitis virus. In the blocking format all non-Henipavirus
antisera were not reactive relative to the set threshold of 15%I. Antiserum against NiV cross reacts to a high level in both binding and
blocking assays.
The HeV iELISA and sG-ELISA were also assessed using this panel
of sera. Frequently interpretation of results for the HeV iELISA
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(using the whole virus antigen preparation) was inﬂuenced by signiﬁcant non-speciﬁc reactions evident as high OD values (greater
than 0.2) against the mock antigen. The HeV sG-iELISA showed a
high level of analytical speciﬁcity for HeV antibodies as all nonHenipavirus sera were negative.
3.3. Diagnostic speciﬁcity of Luminex assays
Two panels of HeV antibody negative sera as determined by
virus neutralisation and/or ELISA serology were tested in Luminex
binding and blocking assays to provide evidence for diagnostic
speciﬁcity.
One hundred and thirty ﬁve horse ﬁeld sera which previously
had tested negative in the HeV sG-iELISA were examined in the
Luminex binding and blocking assays. The results in the binding
assay (Table 1) showed that sera had a mean %P value of 0.4 with
standard deviation of 0.12. In the receptor blocking assay, test sera
displayed 0.8 ± 1.42 (mean ± standard deviation) percent inhibition; the positive control sera gave results in the range 93 to 95%I.
During the course of this study, the use of polystyrene beads was
changed to magnetic beads. The results observed here showed good
correlation between using magnetic or polystyrene beads (Table 1).
An additional panel (n = 145) of HeV virus neutralisation negative sera, grouped by an indeterminate result following testing
in the HeV iELISA were further assessed by HeV Luminex assays.
The binding assay showed test sera to have an average 1.2 ± 0.82
(mean ± standard deviation) %P with all results below the provisional 5%P threshold, however one serum reacted to 4.1%P. This
serum panel were also examined by the Luminex blocking assay,
giving an average %I of 2.42 with a standard deviation of 2.98 and a
maximum of 12.4. The results for these sera which were problematic when tested by ELISA differ from results testing other negative
sera; suggesting that the blocking format may be more affected by
serum sample characteristics than the binding assay.
In addition, sera with an assigned negative status (designated
by clinical and or serological data for virus neutralisation and/or
ELISA), total testings were made, respectively, of 277 (binding
assay) and 267 (blocking assay) sera (Fig. 3). Results provided support for the assigned provisional cut-off thresholds; 5%P control for
the binding assay and 15%I for the receptor blocking assay.
3.4. Use of Luminex assays for post infection and post vaccination
sera
The Luminex assays were assessed further using sera derived
from horses naturally infected with HeV during the original outbreak in 1994, and from other HeV outbreaks. A total of twenty
one post infection sera were examined by ELISA, virus neutralisation and the Luminex assays. All sera tested were positive by virus
neutralisation and above the cut off value of 1000 MFI using the
Luminex binding assay. The results showed the higher the virus
neutralisation titre, the higher the Luminex binding and blocking
results using both HeV sG and NiV sG coated beads (Table 2).
Fifty four sera from horses that had been vaccinated with the
commercially available Hendra virus vaccine (Equivac HeV) which
contains the soluble G protein were assessed by the ELISA, virus
neutralisation and Luminex binding and blocking assays. The HeV
iELISA produced inclusive results due to binding in the mock antigen wells, whereas the sG-iELISA returned positive results for all the
sera. Using the Luminex assays, the vaccinated horse sera displayed
high levels of greater than 50.3%P control in the binding assay and
above 22%I for the blocking assay using the beads coated with soluble G (Fig. 4). Serum from one horse (12-03417-0001) produced
low results in the Luminex and ELISA however this correlated with
the virus neutralisation negative result for this serum.

Fig. 3. Distribution of Luminex binding and blocking assay results for sera previously
determined to be henipavirus antibody negative (binding assay n = 277, blocking
assay n = 267), 21 post-infection sera and 54 post vaccination sera. Status assigned by
clinical and or serological data (virus neutralisation and/or ELISA). Luminex binding
and blocking assay thresholds were set at 5%P and 15%I, respectively.

Fig. 4. Correlation of HeV virus neutralisation antibody with HeV sG iELISA, Luminex
binding and Luminex blocking assay for sera collected from ﬁfty four horses following vaccination with Equivac HeV. Note sera with titres of greater than 256 were
assigned a nominal titre of 512 for the purpose of representation in the plot.
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Table 1
Results using magnetic or polystyrene beads in Luminex binding and blocking assays of horse ﬁeld sera determined as negative by HeV sG iELISA.
Luminex binding assay (MFI)

No serum control
Neg horse serum
Pos serum (Tho)
Pos serum (Tam)
Test sera (average ± standard deviation)1
1
2

Luminex blocking assay (% inhibition)

Magnetic HeV sG

Polystyrene HeV sG

Magnetic HeV sG

Polystyrene HeV sG

43
118
24,989
26,666
99 ± 301

43
92
23,599
25,882
66 ± 291

0
−1
93
95
0.8 ± 1.422

0
−1
96
97
0.52 ± 1.272

135 normal horse sera were assessed in the Luminex binding assay.
126 normal horse sera were assessed in the Luminex blocking assay.

3.5. Review of assay thresholds
Receiver-operator curve (ROC) analysis using assigned positive or negative status of all sera assessed by Luminex binding
and blocking assays was used to evaluate provisional thresholds.
Results are summarised in Table 3 suggest that an improvement
in assay performance could be obtained by marginal alterations to
the provisional thresholds, speciﬁcally, the binding assay from 15 to
12.45 and the blocking assay from 5 to 3.67. However conﬁdence
intervals have considerable overlap and the different thresholds
affected the result determination for only one serum. As a working resolution, a zone of equivocal determination for results falling
between 10 and 15 for the binding assay and from 3 to 5 in the
blocking assay was deﬁned. Samples with results falling within
these zones would be subject to qualiﬁed reporting and/or additional assessment.

3.6. Use of Luminex assays for naturally infected dog sera
The two serum samples taken on the 20th and 26th July 2011
(2011/Mount Alford, QLD no. 1 and 2011/Mount Alford, QLD no. 2)
from a naturally HeV-infected dog were examined together with
dog sera from other HeV infected premises obtained throughout
2011. The Luminex binding assay showed that a high level of HeV
speciﬁc antibodies were present in the two blood samples taken
from the HeV infected dog with results of 22,182 MFI and 12,241
MFI (Table 4). All other dog sera tested in the Luminex binding
assay had MFI values below 230. In the Luminex blocking assay the

two blood samples taken from the HeV infected dog had 88% and
61% inhibition while results for all the other dog samples tested
showed very low levels of inhibition below 3%. All the dog samples
were also examined by HeV iELISA, sG-iELISA and virus neutralisation. Many of the dog sera tested in the HeV iELISA produced
non-speciﬁc reactors preventing conclusive determination by that
assay. The HeV sG-iELISA also produced some non-speciﬁc positive
results as determined by the correlating Luminex and HeV virus
neutralisation assays showing a negative antibody status. In comparison to the ELISAs, the Luminex assays look to be a useful tool
for testing naturally HeV infected dog sera.

4. Discussion
Serology for BSL 4 agents can be problematic in the absence
of appropriate containment facilities; hence the development of
assays that do not require live virus is advantageous. Assays
applied at the time of initial emergence of the disease will generally require technical and interpretive reﬁnement as observations
and data accumulate. However, the validation of these assays for
new or emerging viruses frequently presents additional challenges
due to the lack of well characterised sera. This is exacerbated in
such fulminant disease as HeV by the high early mortality and a
policy of immediate euthanasia upon conﬁrmed detection. Serology procedures applied to date at the Australian Animal Health
Laboratory (PC3 and PC4 containment) have included virus neutralisation, ELISA and more recently the Luminex-based ﬂuorescent
bead assays. The availability of recombinant expressed proteins has

Table 2
Assessment of sera from horses naturally infected with HeV by ELISA, virus neutralisation, Luminex binding and blocking assays.
HORSE SERA year/location/number

HeV iELISA
(OD)

HeV sG iELISA
(S/P)

HeV neutralisation
(titre)

HeV sG Luminex
binding (% Pos)

HeV sG Luminex
blocking (% inhibition)

2008/Redlands, QLD/no. 1
2008/Redlands, QLD/no. 2
2008/Redlands, QLD/no. 3
2008/Proserpine, QLD/no. 1
2008/Redlands, QLD/no. 4
2008/Redlands, QLD/no. 5
2008/Redlands, QLD/no. 6
2008/Hendra, QLD/no. 1
2008/Redlands, QLD/no. 7
2006/QLD/no. 1
2009/Cawarral/no. 1
2009/Cawarral/no. 2
2009/Cawarral/no. 3
2009/Cawarral/no. 4
1994/Hendra, QLD/no. 1
1994/Hendra, QLD/no. 2
1994/Hendra, QLD/no. 3
1994/Hendra, QLD/no. 4
1994/Hendra, QLD/no. 5
1994/Hendra, QLD/no. 6
1994/Hendra, QLD/no. 7

1.8
0.99
0.57
1.79
1.7
1.58
1.8
0.44
0.97
0.55
0.86
1.32
1.38
1.52
1.40
1.63
1.66
0.61
1.15
1.11
1.47

1.83
1.76
1.38
1.63
1.8
1.87
1.71
0.03
1.44
0.02
2.18
2.79
1.81
2.8
1.58
1.66
1.71
0.15
1.52
1.54
1.64

2048
4096
128
512
2048
2048
4096
16
2048
20
64
1024
16
16
640
640
1280
20
640
640
640

104
103
96
103
105
106
104
6
97
4
32
78
104
103
104
104
104
35
104
100
103

93
91
76
77
95
95
85
29
81
15
61
67
90
89
95
95
92
18
94
88
93

Assay positive detection thresholds are: HeV iELISA OD > 0.2; HeV sG ELISA S/P > 0.4; HeV virus neutralisation titre ≥2; HeV Luminex binding % P ≥ 5%; He V Luminex blocking
%I ≥ 15%.
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Table 3
Assessment of assay thresholds using results from ROC analysis.
(a) Luminex blocking assay
Criterion

Sensitivity

95% CI

Speciﬁcity

95% CI

100.00
95.24

83.9–100.0
76.2–99.9

100.00
100.00

98.6–100.0
98.6–100.0

Criterion

Sensitivity

95% CI

Speciﬁcity

95% CI

>3.67
>5

100.00
95.24

83.9–100.0
76.2–99.9

99.28
99.64

97.4–99.9
98.0–100.0

> 12.45
> 15
(b) Luminex binding assay

allowed for improvements, particularly to reduce the frequency of
non-speciﬁc reactions encountered in ELISAs using crude disrupted
virus. As a further reﬁnement to testing procedures, this study has
shown that the henipavirus Luminex binding and blocking assays
are effective for HeV serology in the assessment of equine and
canine sera and are advantageous particularly in the resolution of
indeterminate ELISA results without further recourse to virus neutralisation serology. While progressive validation of this approach
remains dependent on the availability of infrequent positive samples generated in episodic outbreaks, the Luminex assay have been
shown to perform better than the conventional ELISAs currently in
use at AAHL in terms of both sensitivity and speciﬁcity.
The results supplement other serological studies in Australia
and Africa which have utilised Luminex serology assays to demonstrate evidence for henipavirus infection (Bossart et al., 2005, 2007;
Hayman et al., 2011; Peel et al., 2012, 2013; Dups et al., 2012;
Playford et al., 2010). In particular, this study has explored more
extensively the relative performance characteristics of ELISAs and
Luminex and evaluated more recent developments in assessments
of post-infection canine sera and post vaccination equine sera.
The Luminex binding assay has a more conventional indirect
detection format, allowing recognition of both neutralising and
non-neutralising antibodies targeting the HeV G protein (Bossart
et al., 2007). Analytical sensitivity relative to the HeV virus neutralisation favoured the Luminex by a factor of approximately 2,
though this margin is of no practical value for predicting diagnostic performance. The Luminex receptor-blocking assay has a
narrower speciﬁcity, being limited to antibodies in the test sample
which may interfere with binding of the labelled ephrin B receptor.
Hence the assay is described as a neutralisation test surrogate and

has been shown to be uninﬂuenced by binding of non-neutralising
monoclonal antibodies against G protein (Bossart et al., 2007). The
assay therefore has potential as a conﬁrmatory test for speciﬁcity
of results from the binding assay or as a test that would remove the
need for conﬁrmatory virus neutralisation serology. Evidence for
this higher speciﬁcity is also suggested from analytical speciﬁcity
results presented. However the test has a detection range approximately half that of the virus neutralisation; relative to the binding
assay analytical sensitivity is reduced by a nine-fold factor. Nevertheless the relevance of this margin to diagnostic performance
is difﬁcult to assess, particularly given the dearth of post infection
antibody-positive sera. Other than for the expected cross-reactions
with NiV, both assays showed a high level of analytical speciﬁcity.
Diagnostic speciﬁcity was assessed in Luminex binding and receptor blocking assays using a total of 277 (binding) and 267 (blocking)
sera with an assigned negative status as determined by virus neutralisation and/or ELISA. All produced low MFI results and allowed
provisional thresholds to be set at 5% percent positive control and
15% for the receptor blocking assay.
The commercial release in 2012 of the Equivac HeV vaccine
for use in Australian horse populations (companion, farm and racing) has resulted necessarily in a modiﬁcation to the “ﬁtness for
purpose” of serology assays which incorporate the HeV G protein,
including the Luminex and ELISA assays described in this publication. The vaccine induces detectable antibody against G protein as
is evident in this assessment of 54 vaccinated horses which showed
an average of 93%P control. As a consequence and for external
reporting, in reports of results for antibody against G protein, a
comment is inserted “The currently available serology assays do not
distinguish between antibodies due to natural infection and those due

Table 4
Evaluation of HeV detectable antibody in canine ﬁeld sera collected from dogs located in proximity to a conﬁrmed equine HeV infection.
DOG SERA year/location/number

HeV iELISA OD
(mock Ag OD)

HeV sG-i ELISA
(S/N)

Virus
neutralisation

Luminex
binding (MFI)

Luminex blocking
(% inhibition)

Interpretation

2011/Mount Alford,QLD/no. 1
2011/Mount Alford,QLD/no. 2
2011/Biddadaba, QLD/no. 1
2011/Biddadaba, QLD/no. 2
2011/Biddadaba, QLD/no. 3
2011/Biddadaba, QLD/no. 4
2011/Biddadaba, QLD/no. 5
2011/Biddadaba, QLD/no. 6
2011/Wardell, NSW/no. 1
2011/Zillmere, QLD/no. 1
2011/Zillmere, QLD/no. 2
2011/Zillmere, QLD/no. 3
2011/Chinchilla, QLD/no. 1
2011/Currumbin Valley, QLD/no. 1
2011/Tintenbar, NSW/no. 1
2012/Mackay, QLD/no. 1

2.82 (0.09)
2.53 (0.22)
0.34 (0.11)*
0.31 (0.14)*
0.22 (0.15)*
0.25 (0.11)*
0.23 (0.06)*
0.33 (0.12)*
0.16 (0.05)*
3.08 (2.96)*
3.32 (3.42)*
2.88 (2.52)*
0.1 (0.05)
0.38 (0.15)*
0.59 (0.44)*
0.25 (0.06)*

3.02
3.17
0.05
0.02
0.02
0.03
0.02
0.02
0.03
1.84**
1.94**
2.64**
0.06
0.17
0.18
0.02

22,182
12,241
105
74
43
89
83
95
144
97
109
107
110
80
57
33

88
61
3
0
0
0
1
1
1
1
1
1
2
1
0
2

Positive
Positive
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative

2012/Mackay, QLD/no. 2

0.2 (0.05)*

0.01

Positive with a titre >1:16
Positive with a titre of 128
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Insufﬁcient sera***
Indeterminate: sample toxicity
at dilutions less than 1:16***
Negative

229

1

Negative

*
**
***

Inconclusive result due to binding in mock antigen well.
Non-speciﬁc sG ELISA result.
These animals were negative for HeV RNA by PCR.
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to vaccination. Any positive result must be interpreted in the context of
the animal’s vaccination history”. This limitation is presently being
addressed at this laboratory through the development of ELISA
and Luminex assays which are speciﬁc for alternative target proteins such as M, F and/or N. The successful development of these
assays will provide the necessary tools for differentiating infected
from vaccination-derived antibody, commonly referred to as the
DIVA (differentiating infected and vaccinated animals) approach.
Instances which may be affected by the qualiﬁcation applied to the
results of assays detecting anti-G antibody would include assessment of vaccinated (or possibly vaccinated) animals for the absence
of HeV exposure. This is expected to become necessary most frequently should an outbreak occur in the vicinity of vaccinated
animals. For the international movement of vaccinated horses, the
preferred option is considered to be the recognition of a vaccination certiﬁcate without recourse to laboratory testing; recently this
process has been allowed by Hong Kong.
While the zoonotic potential of HeV has been evident since
the initial outbreak and subsequent laboratory based studies
(Williamson and Torres-Velez, 2010), the detection in 2011 and
2012 of natural HeV infection in dogs has been a signiﬁcant development in the epidemiology of this virus. As there is evidence
that these infections can be asymptomatic, laboratory testings
for agent and antibody will be key investigative approaches. This
study provides some evidence for the potential use of Luminex
in canine HeV antibody assessment; in addition it should be
noted that indirect ELISA-based approaches may be prone to nonspeciﬁc binding effects which lessen conﬁdence in results. However
Luminex binding and blocking assay results correlated well with
results using virus neutralisation. While validation studies are
required to establish fully the relative merits of the assays, these
early determinations are favourable for the use of Luminex.
The results obtained in this study involving horses and dogs supplement the ﬁndings by Bossart et al. (2008) to demonstrate the
potential for henipavirus Luminex assays to become used widely
for diagnostic henipavirus serology. Other diagnostic laboratories
in Australia are currently developing microsphere immune-assays
for detection of HeV which could allow the use of this assay across
Australia for diagnostic use in the future. Advantages, evident for
the henipavirus Luminex binding and blocking assays include short
testing time, a high level of sensitivity and speciﬁcity, the absence of
a requirement for PC4 bio-containment and multiplexing capability allowing simultaneous investigation for several disease agents.
A challenge is presented in the context of applying the novel
assay (Luminex) for detection of an emerging disease for which
very few retrospective positive samples are available to determine
validation and ﬁtness. The frequent requirement to assess acute
disease samples for antibody which may not have developed serves
to emphasise the need for both agent and antibody detection in
diagnostic evaluations. Signiﬁcantly, this assessment of Luminex
assays used sera that were determined as positive in virus neutralisation and/or ELISA and it is therefore not possible to infer the
diagnostic characteristic of the assay under these limitations. With
performance characteristics that are equal to or better than ELISA
and virus neutralisation, it is predicted that Luminex assays will
become a versatile tool in disease investigation, epidemiological,
and surveillance studies for the detection of henipavirus speciﬁc
antibodies in the future.
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